{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:03:03Z","timestamp":1790258583006,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Clinical Significance: Cystic fibrosis may remain undiagnosed until adolescence, when recurrent respiratory infections and bronchiectasis are attributed to a previous severe infection. Case Presentation: We report the case of a male adolescent in whom approximately five years elapsed between microbiologically confirmed pulmonary tuberculosis in July 2021 and recognition of cystic fibrosis in August 2026. Archived records documented two sputum specimens that were acid-fast bacilli smear-positive (1+) and culture-positive (1+) for Mycobacterium tuberculosis complex. During adolescence, persistent bronchiectasis, recurrent Gram-negative respiratory infections, digital clubbing, and repeated Pseudomonas aeruginosa isolation prompted etiologic reassessment. A single documented sweat chloride concentration was 114 mmol\/L. CFTR analysis of blood collected on 18 August 2026, reported on 16 September 2026, identified homozygous c.1521_1523delCTT (p.Phe508del; F508del), providing molecular confirmation. Spirometry showed FEV1 2.69 L (79.6% predicted), FVC 3.73 L (91.56% predicted), and FEV1\/FVC 72.01% (z-score \u22122.58), consistent with airflow obstruction; without total lung capacity measurements, restriction or a mixed ventilatory defect could not be confirmed. The previously recorded azithromycin regimen was 500 mg orally three times weekly. Tobramycin inhalation solution 300 mg\/5 mL was prescribed as one ampoule twice daily for 28 days, followed by 28 days off, with three planned cycles and salbutamol 15 min before administration. Management of cystic fibrosis also included airway-clearance therapy, dornase alfa 2.5 mg once daily, a high-calorie diet, pancreatic enzyme replacement, and vitamin supplementation. Longitudinal post-treatment spirometry, anthropometry, and validated quality-of-life measurements were not available. Conclusions: Previous pulmonary tuberculosis should not terminate etiologic investigation when bronchiectasis, repeated Pseudomonas aeruginosa isolation, digital clubbing, or progressive structural lung disease persists. Earlier recognition may permit earlier coordinated cystic fibrosis care and genotype-appropriate CFTR-modulator assessment.<\/jats:p>","DOI":"10.3390\/diagnostics16193102","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:26:11Z","timestamp":1790256371000},"page":"3102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Tuberculosis: Late Diagnosis of Cystic Fibrosis in an Adolescent with Bronchiectasis and Recurrent Pseudomonas aeruginosa Isolation: A Case Report"],"prefix":"10.3390","volume":"16","author":[{"given":"Oana Mariana","family":"Mihailov","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf\u00e2ntul Spiridon\u201d Clinical Hospital of Pneumophthisiology, 800552 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6620-7851","authenticated-orcid":false,"given":"Valerii","family":"Lu\u021benco","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf. Apostol Andrei\u201d County Emergency Clinical Hospital, 800578 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"\u021aocu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf. Apostol Andrei\u201d County Emergency Clinical Hospital, 800578 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-9490","authenticated-orcid":false,"given":"Raul","family":"Mihailov","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf. Apostol Andrei\u201d County Emergency Clinical Hospital, 800578 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-8749","authenticated-orcid":false,"given":"Loredana","family":"Stav\u0103r Matei","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf. Ioan\u201d Children\u2019s Emergency Hospital, 800487 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"\u021aocu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Research Center in the Medical-Pharmaceutical Field, \u201cDun\u0103rea de Jos\u201d University, 800008 Galati, Romania"},{"name":"\u201cSf. Apostol Andrei\u201d County Emergency Clinical Hospital, 800578 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jcf.2024.03.008","article-title":"ECFS standards of care on CFTR-related disorders: Identification and care of the disorders","volume":"23","author":"Simmonds","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.lpm.2017.04.010","article-title":"The diagnosis of cystic fibrosis","volume":"46","author":"Vermeulen","year":"2017","journal-title":"Presse Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(18)31554-X","article-title":"Bronchiectasis in children: Diagnosis and treatment","volume":"392","author":"Chang","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2002990","DOI":"10.1183\/13993003.02990-2020","article-title":"European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis","volume":"58","author":"Chang","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"210105","DOI":"10.1183\/20734735.0105-2021","article-title":"Management of children and adolescents with bronchiectasis: Summary of the ERS clinical practice guideline","volume":"17","author":"Chang","year":"2021","journal-title":"Breathe"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcf.2021.09.017","article-title":"Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis","volume":"21","author":"Ruffin","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e00138-18","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic Fibrosis and Pseudomonas aeruginosa: The Host-Microbe Interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5588\/ijtld.22.0566","article-title":"Post-TB bronchiectasis: From pathogenesis to rehabilitation","volume":"27","author":"Guan","year":"2023","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S1473-3099(23)00004-X","article-title":"Post-tuberculosis sequelae in children and adolescents: A systematic review","volume":"23","author":"Igbokwe","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12098-023-04912-2","article-title":"Post-tuberculosis sequelae in children","volume":"91","author":"Goyal","year":"2024","journal-title":"Indian J. Pediatr."},{"key":"ref_14","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis, World Health Organization. Module 4: Treatment\u2014Drug-Susceptible Tuberculosis Treatment."},{"key":"ref_15","unstructured":"World Health Organization (2022). WHO Operational Handbook on Tuberculosis, World Health Organization. Module 5: Management of Tuberculosis in Children and Adolescents."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4187\/respcare.09540522","article-title":"Cystic fibrosis pulmonary guidelines: Airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ncp.10899","article-title":"Update on the management of vitamins and minerals in cystic fibrosis","volume":"37","author":"Sankararaman","year":"2022","journal-title":"Nutr. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"198","author":"Kloster","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4187\/respcare.09540733","article-title":"Airway-clearance therapy guidelines and implementation","volume":"54","author":"Lester","year":"2009","journal-title":"Respir. Care"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:32:23Z","timestamp":1790256743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":28,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["diagnostics16193102"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16193102","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}